You are viewing: Mexico In Vitro Diagnostics (IVD) Quality Control Market analysis

The Mexico In Vitro Diagnostics (IVD) Quality Control Market was valued at $13.6 Million in 2025 and projected to reach to $16.7 Million by 2030, representing a compound annual growth rate of 4.3%. Mexico's In Vitro Diagnostics Quality Control Market is experiencing steady growth driven by enhanced laboratory standardization initiatives and stricter regulatory compliance mandates.

Mexico In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights

  • Mexico's market reflects steady demand driven by increasing laboratory standardization, regulatory compliance requirements, and the expansion of diagnostic testing infrastructure across the country.
  • The growth trajectory in Mexico is supported by rising healthcare investments and the adoption of quality assurance protocols in clinical laboratories. During the 2025–2030 forecast period, Mexico's IVD quality control sector will benefit from enhanced focus on diagnostic accuracy and patient safety standards.
  • Mexico's market expansion is underpinned by growing awareness among healthcare providers regarding the importance of quality control in reducing diagnostic errors and improving clinical outcomes.
  • The regulatory environment in Mexico continues to strengthen, creating sustained demand for quality control solutions and services in the in vitro diagnostics space..

Key Market Statistics

  • CAGR (2025-2030) 4.3% CAGR
  • Market Size, 2025 ~USD 13.6 Million
  • Forecast, 2030 ~USD 16.7 Million
  • Country Mexico

Mexico In Vitro Diagnostics (IVD) Quality Control Market Overview

Market Valuation :

Mexico's IVD Quality Control Market is valued at USD 13.6 million in 2025, with projected growth to USD 16.7 million by 2030, representing a steady expansion in diagnostic quality assurance infrastructure.

Regulatory Compliance Driver :

Increasing regulatory compliance requirements from Mexican health authorities and COFEPRIS are pushing laboratories to adopt standardized quality control measures, directly boosting market demand.

Laboratory Standardization Growth :

Mexico's diagnostic testing infrastructure is expanding rapidly, with hospitals and clinical laboratories increasingly investing in quality control systems to meet international standards and improve diagnostic accuracy.

Steady Growth Trajectory :

At a CAGR of 4.3%, Mexico's market demonstrates consistent growth below the global average of 5.5%, reflecting a developing market with untapped potential for quality control solutions.

Mexico In Vitro Diagnostics (IVD) Quality Control Market Dynamics

  • The expansion of diagnostic testing infrastructure across public and private healthcare facilities is creating sustained demand for quality control solutions.
  • As Mexican laboratories modernize operations to meet international standards and improve diagnostic accuracy, investment in quality control systems continues to accelerate. The market's 4.3% CAGR reflects Mexico's position as a developing healthcare market with significant growth potential.
  • Increasing awareness of diagnostic quality among healthcare providers and regulatory bodies is expected to drive adoption of advanced quality control technologies.
  • Strategic opportunities exist for vendors targeting mid-sized laboratories and regional healthcare networks seeking cost-effective quality assurance solutions tailored to Mexico's healthcare landscape..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Mexico's IVD Quality Control Market is valued at USD 13.6 million in 2025 and will reach USD 16.7 million by 2030.
      • Mexico's market is growing at a CAGR of 4.3%, driven by regulatory compliance and laboratory standardization initiatives.
      • Mexico's healthcare sector is increasingly prioritizing diagnostic accuracy and quality assurance in clinical laboratories.
      • Mexico's regulatory environment and rising healthcare investments are key catalysts for sustained market expansion through 2030.

      In Vitro Diagnostics (IVD) Quality Control Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 5.5% from 2025 to 2030
      Largest Segment QUALITY CONTROL PRODUCTS (Product & Service)
      Market Size Base Year (Billions) ~USD 1.65 (2025)
      Revenue Forecast (Billions) ~USD 2.15 (2030)
      Segments Covered Product & Service, Type, Technology, Manufacturer Type, End User

      Mexico In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Solutions
      • Quality Assurance Services
      • Quality Control Products

      By Type

      • Independent Controls
      • Instrument-Specific Controls
      • Other Controls
      • Serum/Plasma-Based Controls
      • Urine-Based Controls
      • Whole Blood-Based Controls

      By Technology

      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Other Technologies

      By Manufacturer Type

      • Original Equipment Manufacturer Controls
      • Third-Party Controls

      By End User

      • Academic & Research Institutes
      • Clinical Laboratories
      • Hospitals
      • Other End Users

      Target Audience

      • IVD Equipment Manufacturers : Manufacturers need Mexico-specific market data to develop localized product strategies, understand regulatory pathways through COFEPRIS, and identify distribution partnerships with Mexican laboratory networks.
      • Quality Control Solution Providers : Vendors require detailed insights into Mexico's laboratory standardization trends, compliance requirements, and purchasing behaviors to tailor quality control offerings and establish market presence effectively.
      • Healthcare System Administrators : Hospital networks and laboratory directors need market intelligence to benchmark quality control investments, understand best practices, and justify budget allocations for diagnostic infrastructure improvements.
      • Regulatory and Compliance Consultants : Consultants advising healthcare organizations need Mexico-specific regulatory landscape data, compliance trends, and market adoption patterns to guide clients through quality control implementation.
      • Investment and Strategy Firms : Private equity, venture capital, and strategic consulting firms require Mexico market forecasts and growth projections to evaluate investment opportunities in diagnostic quality control and healthcare technology sectors.

      Key Companies in the Mexico In Vitro Diagnostics (IVD) Quality Control Market

      CompanyHQOwnershipStrongest segments
      BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers),
      CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS),
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products,
      DIASORINItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
      UNILABSSwitzerlandPrivate CompanyCore laboratory testing,Medical imaging services,Pathology and centres of excellence,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services,
      THERMO FISHER SCIENTIFIC, INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula),
      LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
      BIO-TECHNE CORPORATIONUnited StatesPublic CompanyProtein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays,
      MICROBIX BIOSYSTEMS INC.CanadaPublic CompanyAntigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium,
      GRIFOLS, S.A.SpainPublic CompanyBiopharma (plasma-derived medicines),Diagnostic,Bio Supplies,

      BIOMERIEUX S.A.

      bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

      CEPHEID INC.

      Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.

      IMMUCOR, INC.

      Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.

      DIASORIN

      DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      UNILABS

      Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.

      THERMO FISHER SCIENTIFIC, INC.

      Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

      ABBOTT

      Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.

      LGC LIMITED

      LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.

      DANAHER CORPORATION

      Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.

      SYSMEX CORPORATION

      Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.

      BIO-TECHNE CORPORATION

      Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.

      MICROBIX BIOSYSTEMS INC.

      Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.

      GRIFOLS, S.A.

      Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.

      Reasons to Buy this Report

      • Localized Market Intelligence : Gain deep insights into Mexico-specific market dynamics, regulatory requirements, and competitive landscape essential for developing targeted market entry or expansion strategies in this growing healthcare market.
      • Growth Opportunity Identification : Identify high-potential segments within Mexico's USD 13.6M market, including underserved laboratory networks and regional healthcare facilities seeking quality control solutions aligned with local compliance standards.
      • Regulatory Compliance Roadmap : Understand COFEPRIS requirements and Mexican laboratory standardization mandates that drive quality control adoption, enabling vendors to position solutions that address specific regulatory compliance needs.
      • Competitive Positioning Data : Access Mexico-focused competitive analysis and market share insights to benchmark against local and international players, informing pricing strategies and differentiation approaches for the Mexican market.
      • Investment Decision Support : Make informed investment and resource allocation decisions based on Mexico's 4.3% CAGR trajectory, market valuation forecasts through 2030, and emerging opportunities in diagnostic infrastructure expansion.

      Frequently asked questions

      What is the current size of Mexico's IVD Quality Control Market?

      Mexico's IVD Quality Control Market is valued at USD 13.6 million in 2025.

      What is the projected market size for Mexico by 2030?

      Mexico's IVD Quality Control Market is projected to reach USD 16.7 million by 2030.

      What is the CAGR for Mexico's IVD Quality Control Market?

      Mexico's IVD Quality Control Market is expected to grow at a CAGR of 4.3% from 2025 to 2030.

      What are the primary drivers of growth in Mexico's market?

      Mexico's market growth is driven by increasing regulatory compliance requirements, laboratory standardization, healthcare investments, and heightened focus on diagnostic accuracy and patient safety.

      How does Mexico's market compare to the global IVD Quality Control Market?

      Mexico's CAGR of 4.3% is slightly lower than the global CAGR of 5.5%, reflecting regional market maturity and specific regulatory dynamics within Mexico.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the global IVD quality controls market.

      Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.

      The four steps involved in estimating the market size are as follows:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      The following is a breakdown of the primary respondents:

      In Vitro Diagnostics (IVD) Quality Control Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

      In Vitro Diagnostics (IVD) Quality Control Market

      Data Triangulation

      After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.

      Stakeholders

      • Senior Management
      • End Users
      • Finance/Procurement Department
      • R&D Department

      Report Objectives

      • To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
      • To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status